Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach  by Salto-Tellez, Manuel et al.
ORIGINAL ARTICLE
Clinical and Testing Protocols for the Analysis of Epidermal
Growth Factor Receptor Mutations in East Asian Patients
with Non-small Cell Lung Cancer
A Combined Clinical-Molecular Pathological Approach
Manuel Salto-Tellez, MD,* Ming-Sound Tsao, MD,† Jin-Yuan Shih, MD, PhD,‡
Sumitra Thongprasert, MD,§ Shun Lu, MD, PhD, Gee-Chen Chang, MD, PhD,¶
Joseph Siu-Kie Au, MD,# Teh-Ying Chou, MD, PhD,** Jong-Seok Lee, MD,††
Yuan-Kai Shi, MD, PhD,‡‡ Ahmad Radzi, MD,§§ Jin-Hyoung Kang, MD, PhD,
Sang-We Kim, MD, PhD,¶¶ Soo-Yong Tan, MD, PhD,## and James Chih-Hsin Yang, MD, PhD***
Background: Several randomized phase III studies in advanced
stage non-small cell lung cancer (NSCLC) confirmed the superior
response rate and progression-free survival of using epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line
therapy compared with chemotherapy in patients with activating
EGFR mutations. Despite the need for EGFR mutation tests to guide
first-line therapy in East Asian NSCLC, there are no current standard
clinical and testing protocols.
Methods: A consensus meeting was held involving expert oncolo-
gists, pulmonologists, and pathologists to discuss the current status
and variations in EGFR mutation testing of NSCLC across Asia and
to recommend a standard clinical and laboratory testing approach for
future use.
Results: Currently, EGFR mutation tests are only routinely per-
formed in some East Asian countries and medical centers. The
consensus recommendation was to perform the test in all newly
diagnosed patients with advanced stage nonsquamous lung cancer
and some squamous patients with clinical features associated with
higher prevalence of EGFR mutations. To increase the sensitivity
and specificity of the EGFR mutation tests, tissue acquisition and
pretest sample evaluation are important steps in addition to stan-
dardization of the EGFR mutation test methodology.
Conclusion: A standardized EGFR mutation testing protocol is an
essential step toward realization of personalized medicine in East
Asian NSCLC treatment.
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In the past few years, tremendous progress has been made inthe understanding of the molecular pathology of non-small cell
lung cancer (NSCLC) and the development of molecular tar-
geted treatment against this fatal disease. This has led to epider-
mal growth factor receptor (EGFR) mutations being demon-
strated as the most robust predictive biomarker for response to
EGFR-targeted therapies. In addition to standard clinical exam-
ination, pathology and imaging studies for the diagnosis of
patients with NSCLC, EGFR mutation testing should be con-
sidered as a requirement for the complete diagnosis of NSCLC.
Single-arm studies of first-line EGFR tyrosine kinase
inhibitors (TKI) gefitinib or erlotinib monotherapy in NSCLC
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demonstrated high response rates in patients whose tumor
harbors activating EGFR mutations.1–3 In a large phase III
IRESSA Pan-Asia Study (IPASS) involving advanced stage
non/light smoker East Asian patients with lung adenocarci-
noma randomized to treatment with EGFR-TKI gefitinib or
chemotherapy, significant differences in objective response
rates (ORRs) and progression-free survival (PFS) were re-
ported in favor of patients treated with gefitinib. Further
exploratory biomarker analysis showed that patients with
EGFR-activating mutations achieved superior outcomes in
PFS and ORR when first treated with EGFR-TKI compared
with chemotherapy, whereas patients without EGFRmutation
experienced better PFS when combination chemotherapy was
given first.4 This is despite the results of final analysis
revealing no difference in OS between the EGFR mutation
positive or negative patients after 2 or more years of follow-
up, probably due to the extensive crossing-over of subsequent
treatments.5 Despite no difference in the final OS outcome,
initial use of gefitinib in EGFR mutation positive patients did
result in better quality of life, longer PFS, and higher ORR
than chemotherapy-treated patients.6 The results demonstrate
that clinical selection alone was not sufficient for the best
management of patients with NSCLC, and EGFR mutation
test should be recommended to patients with advanced
NSCLC during the time of initial diagnosis.
Several subsequent clinical trials randomizing patients
with EGFR mutation-positive NSCLC to chemotherapy or
EGFR-TKIs such as the Northeast Japan,7 West Japan
Thoracic Oncology Group Trial (WJTOG),8 and erlotinib
versus gemcitabine/carboplatin in chemonaive patients
with stage IIIB/IV NSCLC with EGFR exon 19 or 21
mutation (ML20981) (OPTIMAL)9 studies have confirmed
the superiority of first-line EGFR-TKI to combination
chemotherapy in terms of PFS and ORR.
Several other phase II to phase III studies suggested
similar predictive outcomes for patients receiving EGFR-TKI
as first-line or subsequent lines of treatment.1–3,10–16 Impor-
tantly, these studies have used different EGFR mutation
testing methodologies, and there has been limited details
regarding the tumor sampling and the pretesting sample
evaluation procedures used from literature. Although EGFR
mutation testing is becoming a standard practice for the
treatment of NSCLC, variances for testing in clinical practice
remain across East Asia.
This clinical and testing protocol collate the expert
opinions and recommendations for EGFR mutation testing
from a panel of medical oncologists, pulmonologists, and
molecular pathologists across East Asia, providing a refer-
ence for further discussion and improvement for management
of patients with NSCLC in the molecular targeted age.
PATIENTS AND METHODS
An expert meeting was held with a panel of medical
oncologists, pulmonologists, and molecular pathologists from
Taiwan, Hong Kong, China, South Korea, Thailand, Malay-
sia, Singapore, and Canada. The objective was to discuss the
current status and variances in EGFR mutation testing of
NSCLC across Asia and to provide recommendations to
standardize the clinical and testing protocols across all Asian
clinical centers and hospitals. The discussions examined
current versus ideal EGFR mutation testing practices, current
local practices, and the barriers to routine EGFR mutation
testing across Asia. The discussions led to the participants
gaining a subtle understanding on the situation of EGFR
mutation testing across these countries, and from there, a
standard approach was established and outlined for EGFR
mutation testing in Asia.
RESULTS AND DISCUSSIONS
Status of EGFR Mutation Testing across Asia
In most East Asian medical centers, hospitals, or clin-
ics, EGFR mutation test are not routinely performed in
patients with NSCLC. A simple survey on the panel of
experts estimated that the proportion of nonsquamous pa-
tients tested for EGFR mutations in their practice across East
Asia, which may vary from 30 to 80%. The rates were closely
associated with whether they were referred to medical cen-
ters, public/private hospitals or clinics, size of the medical
centers or hospitals, and facilities available and clinical ex-
pertise of the medical centers or hospitals. In addition, EGFR
mutation test is not yet available for most of Asian medical
facilities. This is in contrast to some research or academic
medical centers in Japan, Taiwan, Korea, Singapore, Thai-
land, China, and Hong Kong, which routinely (or plan to
routinely) perform the test. As many patients with advanced
NSCLC presenting to local hospitals in these or other Asian
countries are currently excluded from the test, with the shift
in treatment paradigm from cytotoxic chemotherapies to
EGFR-targeted therapy on the basis of the mutation test
results, more patients with NSCLC need to be screened, and
EGFR testing is expected to increase.
Potential Barriers to EGFR Mutation Testing
across East Asia
At present, the cost for EGFR mutation tests in most
countries is funded by the patients or research funds and can
vary from US$150 to several hundred US$. Currently, the
most popular method is direct sequencing; however, many
centers are investigating the use of more sensitive methods
such as Scorpion-amplification refractory mutation system
method and other polymerase chain reaction (PCR)-based
methods. As multiple studies have confirmed the efficacy of
first-line gefitinib in improving the PFS of patients with
NSCLC with EGFR mutations, there is potential for the
national insurance systems to extend coverage for the test and
first-line treatment with EGFR-TKI as reimbursable. Besides
cost, other factors that should be considered in setting up
routine EGFR mutation testing include the number of pre-
liminary screenings and sampling times required for patients,
availability of optimal specimen for testing, challenges in
specimen acquisition, clinical protocol at the medical center
or hospital, turn-around time (TAT), availability of experi-
enced clinical pathologists for the required tests, number of
laboratories capable of performing the test in each country,
communication/coordination efforts between the clinician
and pathologist, and the predefined criteria for the type of
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patients (first-line only or include second- and third-line
patients) who should be tested.
TAT: From Clinical Consultation to the
Management of Treatment
If there is a short order-to-report time, first-line treat-
ment with EGFR-TKI can be initiated once EGFR test results
are released. According to a simple survey on the panel of
experts, the time of patient consultation to the release of test
results may be as quick as 5 days or require as long as 14
days, and treatment with EGFR TKI can be recommended
only within 3 days after the results are released. Most patients
can wait and tolerate a 1 to 2-week order-to-report time.
Patients without EGFR mutations may not benefit from ge-
fitinib treatment at all and should be treated with chemother-
apy.8 Patients should be discouraged from taking EGFR-TKI
if the result for mutation is not available based on the IPASS
results that demonstrated even in patients who are enriched
clinically for EGFR mutations, as much as 40% have no
mutations. Nevertheless, in a terminally ill patients who are
not fit for chemotherapy, a trial of EGFR-TKI may be
justified, provided the family members and the patients have
been informed regarding the possible worsening of symptoms
and disease, based on the IPASS findings.
Several factors may influence the duration of the order-
to-report time. In general, histology and EGFR tests that are
performed within the same pathology laboratory compared
with those performed in separate laboratories would have
shorter order-to-report times. The communication and coor-
dination efforts between clinicians and pathologists in hospi-
tals lacking proper clinical protocols may also contribute to
an increase in the order-to-report time. Most small to medium
sized medical centers or hospitals are not set up to perform
the test in-house and would have to send the tests to accred-
ited clinical molecular pathology laboratories for testing. This
situation could lead to longer order-to-report times.
Technical Challenges and Shortcomings of
Mutation Testing Methodology
The most widely used mutation testing methodology is
direct sequencing of PCR products from amplification of
EGFR exons 18 to 21. This method can detect all types of
mutations, but it is time consuming and its sensitivity can be
limited by contamination of nonmalignant cells in the sam-
ples. Other types of confirmatory tests if required after the
first or second direct sequencing tests are also time consum-
ing. Most tests are conducted using archival formalin-fixed
and paraffin-embedded materials, which may include diag-
nostic bronchoscopic, core or excisional biopsies or previous
tumor resection specimens. Materials obtained by fine needle
aspiration may present difficulties, especially if they have
been obtained from small lung lesions.
In some circumstances, tumor tissue is not available or
suitable for EGFR mutation analysis, and this may apply to a
large proportion of patients with lung cancer. A sensitive and
accurate method to detect EGFR mutation from plasma,
serum or circulating tumor cells DNA can greatly improve
the feasibility of personalized medicine for lung cancer. If the
tissue cannot be obtained, the patient’s plasma is an alterna-
tive choice for DNA extraction.17–19 Nevertheless, the sensi-
tivity and applicability of plasma, serum circulating tumor
cells testing is yet to be established.
Malignant pleural effusion is possible source to collect
malignant cells for molecular studies. Nevertheless, micro-
dissection is difficult to perform on cytology specimens,
which often contain substantial proportions of nontumor
cells. The technique of forming a cell pellet, followed by
formalin fixation and paraffin embedding, allows the avail-
ability of material for conventional bright-field microscopy
examination of the presence and percentage of malignant
cells and, as such, a very good alternative for DNA extraction
and molecular analysis.20–22
There should be standard internal quality control (QC)
procedures implemented and adopted within medical institu-
tions or pathology laboratories to ensure the quality of biopsy
sampled is sufficient and met quality requirements before
EGFR mutation testing.
Other Predictive Biomarkers for EGFR TKI
Therapy
Several markers including EGFR mutations, increases
in EGFR gene copy number, single-nucleotide polymor-
phisms of the EGFR gene, EGFR protein expression, and
KRASmutations have been evaluated as predictive markers to
select patients with NSCLC for increased treatment efficacy
to EGFR-TKI.23 For EGFR mutation testing, many method-
ologies are available. Methodologies such as immunohisto-
chemistry, fluorescence in situ hybridization, and mutational
analysis have all been used in research.24 Many of these
testing methodologies have not been standardized in a clinical
trial setting.24
Current Clinical Screening and Management
Protocols
Although a consensus has not been established in rec-
ommending the type of patients with NSCLC who should be
tested, most participants agreed that Asian patients with
nonsquamous histology, particularly adenocarcinoma histol-
ogy should be routinely tested for EGFR mutations. For
patients with NSCLC of Asian origin with squamous histol-
ogy where the EGFR mutation rates are only between 3 and
5%, clinicians are recommended to consider EGFR mutation
testing but with an option of excluding male and heavy
smokers. Nevertheless, EGFRmutation test may be useful for
Asian male and heavy smokers when they have poor perfor-
mance status or comorbidities. In terms of issues with the
specificity of EGFR testing methodologies, it can often be
resolved and validated using repeated sequencing or more
stringent laboratory protocols. It is recommended that for
EGFR wild-type patients, EGFR-TKI should be reserved for
second or further lines of treatment after patients exhaust
chemotherapy options. Rebiopsy of tumor tissue after disease
progression for further evaluation of new mutation such as
EGFR T790M or other activated pathways such as hepatocyte
growth factor—cMET pathway, should be consider. Use of
clinical information and histology alone to guide first-line
EGFR treatment for patients with NSCLC should be discour-
aged, unless an EGFR mutation test cannot be performed.
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EGFR Molecular Diagnostic Testing—Practical
Laboratory Considerations
This section of the article aims to provide a framework
to understand some practical aspects related to EGFR muta-
tion testing.
EGFR Mutation Testing Model
The operational organization of diagnostic testing of
solid tumors may be such that morphology-based diagnostics
and molecular diagnostics are run in independent laborato-
ries, representing different departmental and management
structures (focused approach) or, alternatively, both aspects
may be run under a single laboratory umbrella that coordi-
nates both the morphologic and the genetic analysis of the
tumors (integrated approach). In practical terms, the inte-
grated approaches to pathology diagnostics provide signifi-
cant advantages that have been emphasized recently25,26 in-
cluding the following:
a. An optimal QA of the tissues, including adequate fixation,
processing, embedding, and storage. This optimal treat-
ment of diagnostic tissues should lead to best possible
histomorphology, immunohistochemistry, and DNA pres-
ervation.
b. A combined interpretative analysis, as the histological
diagnosis may help in interpreting the clinical signifi-
cance of the molecular diagnostic results.
c. The organization of a diagnostic flow within the depart-
ment to improve TAT (see later).
EGFR Mutation Testing Methodology
The EGFR gene is large but the region with clinical
relevance (the catalytic kinase domain) includes only four
relatively small exons 18 to 21, which are analyzable by four
individual PCR reactions, within the constraints of small
amplicon sizes inherent to formalin-fixed and paraffin-em-
bedded materials. The many different approaches to the
analysis of EGFR status in lung cancer have been well
reviewed elsewhere.27,28 Although mutation testing may be
performed using different methods including Sanger direct
sequencing or other more sensitive methods,28 regardless of
the method used, it is important to make sure that the
validation, verification, and quality assurance (QA)/QC of the
test must happen in an accredited laboratory environment. In
view of the relevance of EGFR testing in the Asian clinical
environment, an Asian program for EGFR QA/QC, which
could hold a repository of external QCs for general use, is
recommended.
Figure 1 shows the careful steps for a successful Sanger
sequencing analysis of EGFR mutations. We hereby stress
the degree of necessary redundancy in some of the steps,
which represents a conditio sine qua non to ensure accurate
analyses at all times. All laboratories are encouraged to
participate in an external QA program in EGFR mutational
analysis, perform validation studies to ensure their assay is
sufficiently sensitive in particular for the detection of point
mutations, and report their mutation pickup rates and com-
pare the data with other laboratories in the Asian context.
EGFR Mutation Testing Materials
The starting materials for EGFR mutation analysis are
usually the materials still available in the diagnostic samples.
Thus, EGFR analysis can be performed in materials from (a)
bronchoscopic biopsies from central neoplasms; (b) core
biopsies from peripheral neoplasms, (c) the surgical resection
of the primary tumor, (d) fine needle aspiration or pleural
effusion samples, and (e) biopsy of metastatic lesions. The
cytology cell block technique from malignant pleural exu-
dates may represent an alternative to samples where the
original diagnostic sample has not yield enough materials for
therapeutic testing.
As mutation testing will become more common or
routine, the acquisition of tumor materials especially during
biopsy should take into account the following important
considerations:
a. The biopsy sampling of lung cancer should take into
account the need to perform EGFR therapeutic testing
in addition to diagnostic needs (see later).
b. EGFR preanalytical protocols for best DNA preserva-
tion are essential for successful testing. The type of
fixative and the length of fixation, the age of the paraffin
block, and the conditions for storage are clear determi-
nants of the DNA quality. Optimal fixation and embed-
ding as recommended by the College of American
Pathologists29 or the Royal College of Pathologists of
Great Britain and Ireland are adequate to ensure appro-
priate DNA quality. This issue also highlights the im-
portance of embedding strong internal controls in the
protocol (from DNA extraction to PCR reaction) to
avoid the presence of false negative results, a matter of
FIGURE 1. Steps for the Sanger sequencing analysis of epi-
dermal growth factor receptor (EGFR) mutations.
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importance to take into account when designing QA
reviews.
c. It is essential to review the hematoxylin and eosin stain
of the material to be analyzed, to ensure the nature of
the sample, its adequacy for analysis and, crucially, that
the ratio of tumor versus normal is sufficient for the
reported sensitivity of the test, as the calculations of the
individual laboratory. In most occasions, manual micro-
dissection may be necessary to ensure this.
d. The samples that normally have more material (i.e.,
resection specimens) are not necessarily the ones that
have a higher success rate. This may be related to ade-
quacy of fixation.
e. Most cytology samples may be adequate for analyzing
EGFR mutations,30 provided that the laboratory test has
been validated as well for that purpose.
f. The importance of preanalytic steps can be illustrated by
these figures from the laboratory of one of the meeting
participants: when analyzing samples from their own
hospital (where fixation, embedding, and other preana-
lytical variables are carefully looked after) the unsatis-
factory rate is below 3% whereas, when considering the
broad spectrum or referred cases from all over Asia, the
unsatisfactory rate increases close to 13% (unpublished
data).
EGFR Mutation Testing TAT
This aspect of testing may be determinant, as on occa-
sions the test may take as long as it would require to
empirically observe if the patient will respond to treatment by
first-line EGFR TKI (2–3 weeks).31 Much of the time gap
between when the test is requested and the process indicated
in Figure 2 is initiated may be related to internal issues
between laboratories within the same institutions. One option
to overcome this is by instituting reflex testing for EGFR
mutation. The overall process is depicted in Figure 2. When
this protocol is applied, both the morphologic and genetic
characterization will become available to the oncologist si-
multaneously, thus streamlining the whole therapeutic deci-
sion process.
EGFR Mutation Testing Reporting
Classically, a complete molecular diagnostic report should
include the following components: type of molecular test, re-
sults, diagnostic comment (where applicable), clinical signifi-
cance of the test (in general), materials submitted, clinical
background, methods, references, and signatures. In combined
morphology molecular report: gross description, microscopic
description, and histo/cytopathological diagnosis should also be
included.
Whenever possible, and if the technology applied to the
mutation detection allows it, it is important to report the results
in the right clinical value of the detected mutation. Some
examples of how this can be done include the following:
Y A mutation XXXX is identified in exon XXXX. This is
one of the commonest mutations reported conferring
sensitivity to erlotinib or gefitinib.
Y A mutation XXXX is identified in exon XXXX. This is
an uncommon mutation which, nevertheless, has been
reported as conferring sensitivity to erlotinib or gefitinib
(ideally, a reference should be incorporated).
Y A mutation XXXX is identified in exon XXXX. This is
an uncommon mutation; to our knowledge, the clinical
significance of it is unknown.
Y A mutation XXXX is identified in exon 20. This mutation
is reported to confer resistance to erlotinib or gefitinib.
Y A mutation XXXX is identified in exon 20. This is an
uncommon mutation; to our knowledge, the clinical
significance of it is unknown.
EGFR Mutation Testing—Alternative Testing
Methods
In view of the fact that the majority of laboratories in
this study review use Sanger sequencing as the technique of
choice for EGFR mutation detection, our considerations have
been centered in this method, considered by many as the
“gold standard.” Other approaches have been reported, and
the results are equally successful. Methods such as the dena-
turing high performance liquid chromatography,30 the peptic
nucleic acid-locked nucleic acid clamp,32 the limited copy
number-high resolution melting (LCN-HRM) approach33 or
the amplification refractory mutation system, and DxS EGFR
mutation detection kit4 have shown a good performance with
reported increased sensitivity when compared with Sanger
sequencing. Nevertheless, aspects such as reagent cost, avail-
ability of the technology, or the calculated sensitivity of the
direct sequencing-based home-brew test are strong variables
to choose a testing modality. The latter is particularly impor-
tant: although it is true that alternative techniques are more
sensitive than direct sequencing when working on DNA
dilutions from tumor cell lines, the usefulness of some of
these techniques remains to be demonstrated on paraffin-fixed
FIGURE 2. Overall process of epidermal growth factor re-
ceptor (EGFR) mutation testing turn-around time (TAT) from
request for testing, diagnostic testing to recommendations
for first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
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tumor biopsies. The use of immunohistochemistry by using
mutation-specific antibodies34 can serve as a useful prescreening
tool, although confirmation by other PCR-based methods is
still desirable.
EGFR Mutation Testing—Single Biomarker
versus Multiple Biomarkers
It is the impression of the pathology community that we
are increasingly asked to provide more information from
samples that are getting smaller. This small sample revolution
may have to be revisited in the context of predictive pathol-
ogy and will clearly affect the testing of EGFR and other
mutations. In the future, it is likely that we will be testing for
different biomarkers of the same pathway, as the KRAS/
BRAF paradigm in metastatic colorectal cancer,35 different
biomarkers that are mutually exclusive leading to different
therapeutic options, such as EGFR or KRAS mutation analy-
ses and EML4-ALK rearrangements in lung adenocarci-
noma,36 or perform multiple biomarker tests for several
biologically distinct therapeutic potentials. The latter is ex-
emplified by the Biomarker-integrated Approaches of Tar-
geted Therapy for Lung Cancer Elimination trial,37 in which
additional to their original “diagnostic” sampling, patients’
tumors are characterized for a large panel of biomarkers to
guide multiple therapeutic trials. The need for more generous
sampling at the time of diagnosis, or the introduction of
multiplex biomarker assays, will require a significant change
of mindset in those who are at the first line of the biopsy
taking, such as radiologists or pulmonologists (Figure 3).
Current Recommendations in Other Parts of
the World
The issues of EGFR mutation testing confronted by
pathologists and oncologists are similar worldwide. Never-
theless, the recommendations may differ due to different
proportions of patients with EGFR mutation in a given
population and different practicing environment. A European
workshop established consensus of EGFR mutation testing in
NSCLC among European lung cancer experts.38 It is recom-
mended in European centers that EGFR mutation tests should
be ordered by treating physicians, whereas in Asian centers,
the EGFR mutation test results can preferably be performed
immediately with pathological diagnosis as part of the mo-
lecular pathology diagnosis report. In the National Compre-
hensive Cancer Network guideline, EGFR testing is a cate-
gory 1 recommendation for adenocarcinoma, large cell
carcinoma, and NSCLC not otherwise specified and not
recommended for squamous cell carcinoma. Nevertheless,
the EGFR mutation testing can be considered in Asian pa-
tients with squamous cell carcinoma, although not routinely
performed.
CONCLUSION
All committee members agreed and were confident that
the expert opinions recommended in this article would im-
prove clinical screening of EGFR mutations in East Asian
patients with NSCLC and lead to more rapid and effective
treatment of Asian patients with NSCLC with EGFR-directed
therapies. The protocol will facilitate multiple biomarkers
testing in the future.
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